About Neurophth therapeutics

About company

Neurophth Therapeutics is China's first ophthalmology gene drug research and development company, located in Wuhan Optics Valley Biological City, a national-level biological industrial park. Committed to the research and drug development of gene therapy for eye genetic diseases. Newforth first chose Leber hereditary optic neuropathy (LHON) as a breakthrough. Since 2008, a lot of basic research has been carried out. In 2011, the world ’s first clinical study of gene therapy for Leber hereditary optic neuropathy was completed, and 9 patients participated in clinical research. Leber hereditary optic neuropathy gene therapy patients have been observed for 7 years so far.